Navigation Links
Terahertz imaging may reduce breast cancer surgeries

A promising new technique to ensure complete tumor removal at breast cancer excision is introduced in the May issue of Radiology.

Researchers used light waves in a newly explored region of the electromagnetic spectrum--the terahertz region--to examine excised breast tissue and determine if the removed tissue margins were clear of cancer, with good results. This technology has the potential to eliminate the need for multiple surgeries and tissue samples to get clear surgical margins.

"We found that terahertz light could reliably distinguish between normal breast tissue, tumor and even early-stage 'in situ' cancers in excised tissue samples," said Vincent P. Wallace, Ph.D., lead investigator at TeraView, who worked with Addenbrooke's Hospital in Cambridge, England, in conducting the study. "This technology could aid the surgeon in immediately identifying residual cancer after the main tumor has been removed, thus minimizing the need for additional surgical procedures."

Currently, excised tissue samples must be sent for histopathologic examination, which typically takes several days. Thus, surgeons don't know if all the tumor has been removed until well after the surgical procedure has been completed, and often, repeat surgeries have to be scheduled. For the first time, however, terahertz imaging has the potential to eliminate the need for subsequent procedures by allowing the surgeon to analyze tissue samples during the initial excision procedure.

Terahertz light is located between the infrared and microwave portions of the electromagnetic spectrum. The researchers found that by placing a slice of excised breast tissue on a special quartz plate and exposing it to terahertz light, the light waves reflected from the tissue contained unique information about its state. The researchers were able to distinguish both invasive and noninvasive breast carcinomas from healthy tissue.

Twenty-two excised breast tissue samples were obtained f rom 22 women who underwent either wide local excision or mastectomy to remove breast cancer. All samples were first sliced and imaged with terahertz light, and then submitted for histopathologic analysis. Imaging took less than five minutes.

"There were substantial differences in the optical properties of normal and diseased tissue," Dr. Wallace said. The size and shape of the diseased regions at terahertz imaging were compared with those at histopathologic examination, with good results. All but three samples yielded invasive cancers. In total, there were two invasive lobular carcinomas, 14 invasive ductal carcinomas, three mixed invasive ductal and lobular carcinomas, two cases of pure ductal carcinoma in situ and one dense radial scar.

In breast cancer excision surgery, the aim is to remove the entire tumor with an adequate margin of normal tissue, while minimizing the amount of healthy tissue being removed. If a histopathologist analyzes the tissue and finds tumor at or near the edges, this indicates that there is a higher chance of cancer recurrence. A second operation is required to remove more tissue, involving additional hospital resources and increased risk of patient morbidity. Thus, there is a clinical need to accurately define the margins of the tumor during surgery.


'"/>

Source:Radiological Society of North America


Related biology news :

1. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
2. Duke engineers develop new 3-D cardiac imaging probe
3. Confocal imaging promises early detection of skin cancer
4. Newer imaging techniques may lead to over-treatment
5. Researchers use 3-D imaging system to unveil swimming behavior of microscopic plankton
6. Microscopic brain imaging in the palm of your hand
7. New imaging technology shown to detect pancreatic inflammation in type 1 diabetes
8. Purdues gold nanorods brighten future for medical imaging
9. PET imaging reveals the immune system at work
10. New technique puts brain-imaging research on its head
11. T-rays: New imaging technology spotlighted by American Chemical Society
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
Breaking Biology News(10 mins):
(Date:6/22/2016)... NEW YORK , June 22, 2016 /PRNewswire/ ... the growing next generation sequencing (NGS) market include ... adoption of smaller sequencers.  More accessible and affordable ... led to growing demand for consumables including sample ... The Market for Sample Preparation for Next ...
(Date:6/22/2016)... , June 22, 2016   ViaCyte, Inc. , ... stem cell-derived islet replacement therapy for the treatment of ... ISSCR 2016 Annual Meeting.  ISSCR 2016, the Global Stem ... at Moscone West in San Francisco.  ... presentations are as follows:Event: , Focus Session: Tools for ...
(Date:6/22/2016)... 2016  Mesa Biotech Inc., a privately-held, molecular ... designed specifically for point-of-care (POC) infectious disease diagnosis, ... board (SAB). Approved by the executive leadership team ... to advise on the development and commercialization of ... Dr. Steve Young , this world-class team ...
(Date:6/21/2016)... NANJING , China , June ... that a Phase 2 clinical trial for its novel ... statistically significant (p=0.023) and clinically meaningful pain relief against ... the United States , the trial enrolled 146 ... statistically significant (1) analgesia against placebo at week-1 (p=0.024), ...
Breaking Biology Technology: